Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) filed this Current Report on Form 8-K on January 12, 2026. The filing announces preliminary unaudited financial results for the fiscal year ended December 31, 2025, and discloses materials presented at the J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing references the announcement of preliminary unaudited net product sales for the full fiscal year 2025, specifically breaking out sales for LIVMARLI (maralixibat), CHOLBAM, and CTEXLI. It also references preliminary unaudited cash, cash equivalents, and investments.
Note: The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the referenced press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the input text.
Material Changes
The filing does not provide specific comparative data or percentage changes versus the prior period. It serves as a notification that the Company has released preliminary results for the 2025 fiscal year.
Guidance, Outlook, and Risks
The Company presented an investor slide deck at the J.P. Morgan Healthcare Conference on January 12, 2026, which likely contains management commentary and outlook. The filing explicitly states that the Company undertakes no obligation to update, supplement, or amend the materials attached as Exhibit 99.2. No specific risks or contingencies are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific net product sales figures for LIVMARLI, CHOLBAM, and CTEXLI for the year ended December 31, 2025.
- Verify the exact amounts of cash, cash equivalents, and investments as reported in the press release.
- Examine Exhibit 99.2 (Investor Presentation) for updated guidance, pipeline milestones, and management's outlook for 2026.
- Confirm the Company's status as an emerging growth company and any related accounting election disclosures.